Effect of the p38 kinase inhibitor, SB203580, in a model of airway inflammation

被引：0
|
作者：
Birrell, M [1 ]
Haddad, EB [1 ]
McCluskie, K [1 ]
Hele, D [1 ]
Phipps, S [1 ]
Webber, SE [1 ]
Foster, M [1 ]
Belvisi, MG [1 ]
机构：
[1] Rhone Poulenc Rorer Res & Dev, Dagenham Res Ctr, Dept Pharmacol, Dagenham RM10 7XS, Essex, England
来源：
BRITISH JOURNAL OF PHARMACOLOGY | 1998年 / 125卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
89P
引用
收藏
页码：U46 / U46
页数：1
相关论文
共 50 条
  • [31] SB203580, a pharmacological inhibitor of p38 MAP kinase transduction pathway activates ERK and JNK MAP kinases in primary cultures of human hepatocytes
    Henklova, Pavla
    Vrzal, Radim
    Papouskova, Barbora
    Bednar, Petr
    Jancova, Petra
    Anzenbacherova, Eva
    Ulrichova, Jitka
    Maurel, Patrick
    Pavek, Petr
    Dvorak, Zdenek
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2008, 593 (1-3) : 16 - 23
  • [32] Quantitative proteomic and transcriptional analysis of the response to the p38 mitogen-activated protein kinase inhibitor SB203580 in transformed follicular lymphoma cells
    Lin, ZS
    Crockett, DK
    Jenson, SD
    Lim, MS
    Elenitoba-Johnson, KSJ
    MOLECULAR & CELLULAR PROTEOMICS, 2004, 3 (08) : 820 - 833
  • [33] Protective effects of the p38 MAPK inhibitor SB203580 on NMDA-induced injury in primary cerebral cortical neurons
    Liu, Xue-Wen
    Ji, En-Fei
    He, Peng
    Xing, Rui-Xian
    Tian, Bu-Xian
    Li, Xi-Dong
    MOLECULAR MEDICINE REPORTS, 2014, 10 (04) : 1942 - 1948
  • [34] The p38 MAP kinase inhibitor SB203580 enhances nuclear factor-kappa B transcriptional activity by a non-specific effect upon the ERK pathway
    Birkenkamp, KU
    Tuyt, LML
    Lummen, C
    Wierenga, LTJ
    Kruijer, W
    Vellenga, E
    BRITISH JOURNAL OF PHARMACOLOGY, 2000, 131 (01) : 99 - 107
  • [35] p38 Inhibitor SB203580 sensitizes the resveratrol-induced apoptosis in human lung adenocarcinoma (A549) cells
    Li, Haiyang
    Wang, Xiaoping
    Chen, Tongsheng
    Qu, Junle
    JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, 2012, 26 (07) : 251 - 257
  • [36] SB203580, a p38 mitogen-activated protein kinase inhibitor, suppresses the development of endometriosis by down-regulating proinflammatory cytokines and proteolytic factors in a mouse model
    Zhou, Wei-Dong
    Yang, Hui-Ming
    Wang, Qin
    Su, Dong-Yin
    Liu, Fu-An
    Zhao, Min
    Chen, Qiong-Hua
    Chen, Qing-Xi
    HUMAN REPRODUCTION, 2010, 25 (12) : 3110 - 3116
  • [37] Temporary blockade of contractility during reperfusion elicits a cardioprotective effect of the p38 MAP kinase inhibitor SB-203580
    Sumida, T
    Otani, H
    Kyoi, S
    Okada, T
    Fujiwara, H
    Nakao, Y
    Kido, M
    Imamura, H
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2005, 288 (06): : H2726 - H2734
  • [38] The p38 mitogen-activated protein kinase inhibitor, SB203580, activates the serine/threonine kinase Raf-1 in vascular smooth muscle cells.
    Daum, G
    Kalmes, A
    Clowes, AW
    FASEB JOURNAL, 1999, 13 (04): : A470 - A470
  • [39] p38 Mitogen-activated protein kinase inhibitor SB203580 reverses the antianalgesia induced by dextro-morphine or morphine in the mouse spinal cord
    Wu, Hsiang-en
    Sun, Han-Sen
    Cheng, Caleb W.
    Tseng, Leon F.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 550 (1-3) : 91 - 94
  • [40] SB203580, a p38 mitogen-activated protein kinase inhibitor, fails to improve functional outcome following a moderate spinal cord injury in rat
    Stirling, D. P.
    Liu, J.
    Plunet, W.
    Steeves, J. D.
    Tetzlaff, W.
    NEUROSCIENCE, 2008, 155 (01) : 128 - 137
12345